An evaluation of the role of Magnetic resonance Imaging (MRI) in Mucosal Primary Head and Neck Cancer

Not Applicable

Active, not recruiting

• Conditions: Head and Neck Cancer; Cancer - Head and neck

• Registration Number: ACTRN12616000534482
• Lead Sponsor: Dr Myo Min

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-04-26
• Last Update Posted: 22 August 2022

Recruitment & Eligibility

• Status: Active, not recruiting
• Sex: All
• Target Recruitment: 34

Inclusion Criteria

18 years or older
- Have the ability to give informed consent
- Histologically-proven invasive primary squamous cell carcinoma of mucosal primary head and neck region or patients with tumours strongly suspicious for mucosal primary head and neck cancer due to clinical features AND fine needle aspiration (FNA) cytology assessment
- Primary mucosal head and neck cancer (greater than or equal to T2 and/or greater than or equal to N1) AND no evidence of metastatic disease on staging PET/CT or CT (chest +/- abdomen +/- pelvis)
- Patient undergoing curative intent primary radiotherapy +/- chemotherapy

Exclusion Criteria

- Contraindication to MRI studies including significant claustrophobia, pacemaker/implantable defibrillator, implanted metals eg. Intraocular clips, and/or known allergic reaction to Gadolinium (Gd)-DTPA
- Previous radiotherapy and/or surgery in the head and neck region
- Other malignancy (history of malignancy within 5 years)
- Pregnant

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To determine the correlation of pre-, during treatment and post-radiotherapy (+/- chemotherapy) MRI sequences with respect to tumour response at 3 months by PET scan and local control at 12 months which will be determined through radiological assessment (PET scan), physical examination and flexible naso-endoscopy examination. [3 and 12 months post radiotherapy treatment]